NDAORALTABLET
Approved
May 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATAZIA is an oral contraceptive tablet combining estradiol valerate and dienogest in a cyclic regimen, designed to prevent pregnancy through hormonal suppression of ovulation. It is indicated for contraception in women of reproductive age. The drug delivers physiologic levels of estradiol via a valerate ester formulation paired with a progestin to provide cycle control and tolerability.
$0.121MPart D
LOE Approaching1.7 years to LOEProduct is in late-stage lifecycle with minimal Part D claims, suggesting limited market penetration and shrinking commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on NATAZIA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.